Takeda Invests $30 Million in Indonesia's Plasma Industry

Takeda Pharmaceutical Company, a leading Japanese bio-pharmaceutical firm, has announced a significant investment of $30 million (approximately Rp 539 billion) to develop a plasma-derived product ecosystem in Indonesia. This initiative aims to establish a network of plasma banks over the next two years, with the first expected to begin operations by 2027, according to the Indonesian Investment Coordinating Board (BKPM).

Rosan P. Roeslani, the head of BKPM, emphasized that this investment reflects growing global investor confidence in Indonesia's prospects, particularly in the high-tech healthcare sector. He noted that the investment is strategic, not only bringing additional capital but also opening opportunities for technology transfer, human resource development, and the creation of high-skilled jobs.

The partnership aligns with Indonesia's economic transformation agenda, which seeks to enhance competitiveness in various strategic sectors, including healthcare. The government hopes that this collaboration will improve public access to essential plasma-derived medicines, while also fostering a competitive, innovative, and sustainable bio-pharmaceutical industry.

“This investment is strategic, not only bringing additional capital but also opening opportunities for technology transfer, human resource development, and the creation of high-skilled jobs.”Rosan P. Roeslani, Head of BKPM

Japan has been a key strategic partner for Indonesia in terms of investment. Data from BKPM indicates that Japan was among Indonesia's major investors in the first quarter of 2026, contributing approximately $1 billion. Cumulatively, Japanese investments from 2021 to the first quarter of 2026 reached $18.1 billion, with an average growth rate of 13.2% and creating 299,460 jobs.

Through this investment, Takeda aims to not only bolster its presence in the Indonesian market but also contribute to the development of a robust healthcare infrastructure. The Indonesian government is optimistic that the establishment of plasma banks will enhance the availability of vital medical products and strengthen the country’s position in the global supply chain for healthcare.